MD Newsline Dermatology Brief

In this episode of MD Newsline, Kendra Joseph, PA-C, a dermatology physician assistant with over ten years of clinical experience in New York City, breaks down the complexities of managing atopic dermatitis (AD) and the broader eczema umbrella. She clarifies the differences between atopic dermatitis and related conditions like seborrheic dermatitis and contact dermatitis. Joseph addresses the clinical nuances of diagnosing AD across diverse patient populations, focusing on non-classical presentations in skin of color—such as violaceous or hyperpigmented lesions—and the psychological toll of chronic pruritus. The discussion covers practical management strategies for scalp eczema, contrasting over-the-counter oil use with targeted prescription vehicles matched to specific hair textures and styling routines. Finally, she examines the shift from broad topical corticosteroids to targeted topical JAK inhibitors, calcineurin inhibitors, oral JAK inhibitors, and biologics, highlighting the importance of collaborative care, mental health support, and emerging precision medicine.

Episode Highlights

Demystifying the Eczema Umbrella and Clinical Presentations Kendra Joseph, PA-C, clarifies that eczema serves as an umbrella term covering various inflammatory skin conditions. Atopic dermatitis represents the most common variant, classically presenting on flexural surfaces such as the back of the knees, antecubital fossa, and neck. It frequently co-occurs alongside asthma and seasonal allergies as part of the atopic triad. In clinical practice, key diagnostic features include lesion distribution, recurrence in identical locations, seasonal flare cycles, and generalized itching. Joseph notes that while AD is often mischaracterized as purely a childhood disease, many adult patients present with new-onset atopic dermatitis.

Navigating Diagnostic Nuances in Skin of Color and Scalp Care The conversation addresses diagnostic and therapeutic considerations for diverse skin types and hair textures. In darker skin types, AD lesions often present with violaceous (purplish) hues or post-inflammatory hyperpigmentation rather than classic erythema. On the scalp, AD must be differentiated from seborrheic dermatitis. Joseph cautions against applying heavy over-the-counter oils, as common yeast species on the scalp feed on these products and exacerbate inflammation. Instead, clinicians should match prescription vehicles—such as oil-based topicals or lightweight solutions—to a patient's specific hair-styling practices and texture.

Addressing the Burden of Pruritus, Sleep Loss, and Secondary Infections Beyond visible skin lesions, pruritus imposes a severe physical and psychological burden, leading to sleep disruption, missed work, and social withdrawal. Chronic scratching leads to lichenification (thickened, leathery skin). Clinicians must remain vigilant for secondary superinfections, including impetiginized skin characterized by yellow, honey-colored crusting, as well as eczema herpeticum, which presents with painful blisters, fever, and systemic malaise.

Skin Barrier Repair, Emollients, and Flare Trigger Management Optimal management requires pairing prescription therapies with rigorous, personalized skincare routines. Patients should utilize fragrance-free cleansers and thick emollients containing humectants, glycerin, hyaluronic acid, or ceramides immediately after short, lukewarm showers to restore skin barrier integrity. Trigger reduction—including identifying specific metal allergens like nickel in contact dermatitis—should be managed collaboratively to avoid unnecessary lifestyle restrictions.

Therapeutic Escalation: Topicals, Biologics, JAK Inhibitors, and Phototherapy While topical corticosteroids remain a fast-acting option to extinguish acute flares, clinicians must address patient anxiety around steroid overuse or misuse. Non-steroidal topicals, including topical JAK inhibitors and topical calcineurin inhibitors, provide effective alternatives. When AD severely impacts quality of life or affects large body surface areas, care escalates to systemic biologics, oral JAK inhibitors, or phototherapy (narrowband UVB light therapy) for patients seeking non-pharmacological options.

Multidisciplinary Collaboration, Mental Health, and Future Horizons Managing chronic AD requires addressing the psychological sequelae of long-term disease. Joseph advocates for involving psychologists, therapists, allergists, and primary care providers when patients experience disease-related anxiety or burnout. Looking to the future, she highlights the promise of precision medicine to select therapies based on individual genetic profiles and anticipates ongoing advancements toward higher disease clearance rates.

Key Takeaway Managing atopic dermatitis requires a comprehensive, patient-centered approach that extends beyond treating surface lesions to address chronic pruritus, skin barrier repair, and psychological well-being. By tailoring treatment vehicles to individual hair and skin types, utilizing targeted therapies like JAK inhibitors and biologics, and fostering collaborative multi-specialty care, clinicians can achieve high rates of disease clearance and restore patient quality of life.

RESOURCES

Website — https://mdnewsline.com/ Newsletter — https://mdnewsline.com/subscribe/ Kendra Joseph, PA-C — https://www.linkedin.com/in/kendrajoseph/

In this episode of MD Newsline, Dr. Marisa Garshick, a board-certified dermatologist at Medical Dermatology and Cosmetic Surgery Center in New York and Clinical Assistant Professor at Weill Cornell Medicine, discusses modern clinical approaches to atopic dermatitis (AD). Dr. Garshick reframes atopic dermatitis from simple "dry skin" to a complex, chronic type 2 inflammatory disease. She highlights the diagnostic nuances across different skin tones, the biological mechanics of the atopic march, and the profound impact of pruritus on sleep architecture, mental health, and patient quality of life. The conversation explores practical barrier care, Staphylococcus aureus colonization, bleach baths, the skin microbiome, and the clinical distinction between true food allergies and eczema flares. Dr. Garshick also details the therapeutic paradigm shift from broad immunosuppressive medications and traditional topical steroids to targeted biologics, JAK inhibitors, non-steroidal topicals, and phototherapy.

Episode Highlights

Reframing Atopic Dermatitis and Diagnostic Nuances Dr. Garshick emphasizes that atopic dermatitis is a chronic inflammatory skin condition requiring more than over-the-counter moisturizers to heal properly. While classic presentations involve erythematous, pink scaly patches in flexural areas like the antecubital fossa or popliteal fossa, atopic dermatitis in skin of color can present non-classically as dark brown, purple, or ashen gray patches. When clinical presentation is unclear, a skin biopsy should be performed for histopathological confirmation.

Differentiating Adult-Onset Disease and the Atopic March When evaluating adult-onset atopic dermatitis, clinicians must rule out lookalike conditions such as contact dermatitis triggered by fragrances or preservatives. Dr. Garshick also addresses the atopic march—the progression from atopic dermatitis to asthma and allergic rhinitis—reassuring clinicians and parents that while genetic predisposition elevates overall risk, progression across all conditions is not inevitable for every patient.

Type 2 Inflammation, Systemic Burden, and Mental Health The discussion highlights how atopic dermatitis is driven by type 2 inflammatory pathways and specific cytokine pathways that impair skin barrier integrity and drive central itch signaling. The resulting pruritus causes profound sleep disruption, cutaneous pain (burning or stinging sensations), and elevated rates of anxiety and depression. Managing the underlying cutaneous inflammation is critical to improving overall sleep quality and psychological well-being.

Microbiome Dynamics, Infection Control, and Bleach Baths Barrier disruption from scratching allows opportunistic pathogens like Staphylococcus aureus to colonize the skin, triggering recurrent secondary bacterial or viral infections and driving flare-ups. Dr. Garshick explains the role of bleach baths (dilute sodium hypochlorite baths using a quarter-cup of bleach) as an effective method for bacterial decolonization. She also reviews the emerging role of prebiotics, probiotics, and postbiotics in supporting the skin microbiome alongside standard barrier repair.

Dietary Misconceptions vs. True Food Allergies Dr. Garshick addresses common patient misunderstandings surrounding diet and atopic dermatitis. Unnecessary elimination diets can harm growing children, as true food allergies typically manifest as immediate urticaria (hives) rather than eczematous patches. While high glycemic index foods and highly processed carbohydrates may promote generalized inflammation, clinicians should encourage a well-balanced diet rather than blanket food restrictions.

Evolving Therapeutic Options: From Topicals to Targeted Systemics The therapeutic landscape for atopic dermatitis has expanded significantly beyond broad immunosuppressive medications. Management ranges from daily emollient barrier maintenance to phototherapy and advanced targeted therapies, including biologics, JAK inhibitors, and non-steroidal topical agents. Dr. Garshick underscores the importance of maintaining proactive maintenance therapy to sustain disease remission rather than reactively treating flares after barrier breakdown occurs.

Key Takeaway Effective management of atopic dermatitis requires moving beyond simple moisturizers to address underlying type 2 inflammation, restore skin barrier integrity, and suppress pruritus. Utilizing targeted therapies—such as biologics, JAK inhibitors, non-steroidal topicals, and proper decolonization protocols—allows clinicians to achieve long-term disease remission and significantly improve patient quality of life.

RESOURCES

Website — https://mdnewsline.com/ Newsletter — https://mdnewsline.com/subscribe/ Dr. Marisa Garshick — https://weillcornell.org/marisa-garshick-md Medical Dermatology and Cosmetic Surgery Center (MDCS Dermatology) — https://mdcsderm.com/ Weill Cornell Medicine — https://weillcornell.org/ National Eczema Association — https://nationaleczema.org/

In this episode of MD Newsline, Dr. Marisa Garshick, board-certified dermatologist at Medical Dermatology & Cosmetic Surgery and Clinical Assistant Professor of Dermatology at Weill Cornell Medicine, discusses why atopic dermatitis is far more than dry skin. She explores how eczema can present differently across skin tones, the challenges of distinguishing atopic dermatitis from other inflammatory skin conditions, and why visible disease severity does not always reflect the impact of symptoms on patients.

Dr. Garshick also shares practical insights into skincare fundamentals, treatment selection, targeted therapies, the role of the skin microbiome, and strategies for improving long-term disease control. She discusses the impact of itch on sleep, mental health, and daily functioning, as well as emerging approaches to prevention and the future of atopic dermatitis care.

Episode Highlights: Recognizing Atopic Dermatitis Beyond Dry Skin

Dr. Garshick explains that atopic dermatitis is more than simple dry skin and includes an inflammatory component that may require more than moisturization alone. She discusses common clinical features, including itchy, scaly patches and characteristic distributions such as the inner arms and backs of the knees, while emphasizing the importance of considering other diagnoses when evaluating adult-onset disease.

Diagnosing Eczema Across Different Skin Tones

The conversation explores how atopic dermatitis can look different across skin tones and why clinicians should remain attentive to less-classical presentations. Dr. Garshick discusses the importance of clinical evaluation and notes that a skin biopsy may help when the diagnosis is uncertain.

Disease Severity, Itch, and Quality of Life

Dr. Garshick discusses how the extent and thickness of skin lesions can contribute to assessments of severity, but emphasizes that even mild visible disease can have a substantial impact on patients. Persistent itch can disrupt sleep, work, school, and daily functioning, making quality of life an important consideration when evaluating disease control and treatment needs.

The Atopic March and Allergic Disease

Dr. Garshick explains the concept of the atopic march and the potential relationship between eczema, asthma, and allergic rhinitis. She emphasizes that an atopic predisposition does not mean every patient will develop all of these conditions, while highlighting the importance of remaining attentive to potential allergic disease, particularly in individuals with a relevant family history.

Advances in Targeted Atopic Dermatitis Therapies

The discussion explores how a better understanding of the immune mechanisms involved in atopic dermatitis has led to more targeted treatment approaches. Dr. Garshick discusses the evolution from broader immunosuppressive therapies toward targeted immune therapies, including biologics and JAK inhibitors, and how these options have expanded the ability to achieve disease control.

Skin Barrier Care and Treatment Adherence

Dr. Garshick emphasizes that moisturization and skin barrier support remain foundational to atopic dermatitis management, even with newer medical therapies. She shares practical recommendations including short, lukewarm showers, regular use of moisturizer, and selecting products that patients are comfortable using consistently. She also discusses fragrance-free products and barrier-supporting ingredients such as ceramides, hyaluronic acid, and niacinamide.

The Skin Microbiome, Infections, and Flares

The conversation examines how disruption of the skin barrier can increase opportunities for bacterial and viral infections and contribute to recurring problems in some patients. Dr. Garshick discusses the importance of maintaining the skin barrier and explains that approaches such as antibacterial washes or bleach baths may be considered in certain patients with recurrent infections. She also discusses the growing interest in the skin microbiome, while noting that more research is needed to determine how microbiome-directed approaches will fit into future eczema care.

Diet, Food Allergies, and Atopic Dermatitis

Dr. Garshick addresses common questions surrounding diet and eczema, explaining that most patients do not need to follow a specific elimination diet. She discusses situations in which a food diary may help identify a potential relationship between a particular food and flares, while cautioning against unnecessary food restriction and noting that food allergy reactions can present differently from typical eczema.

Long-Term Management and Emerging Therapies

Dr. Garshick discusses the role of phototherapy for selected patients, as well as emerging approaches to prevention and maintenance therapy. She highlights data supporting early moisturization in some infants with a strong family history of allergic disease and emphasizes the goal of maintaining remission rather than simply treating flares after they occur. Looking ahead, she expects continued progress in biologics and JAK inhibitors, along with further research into the skin barrier and microbiome.

Key Takeaway

Atopic dermatitis is more than dry skin, and its impact cannot always be measured by what is visible on the skin. Effective management requires attention to inflammation, itch, sleep and quality of life, skin barrier health, treatment adherence, and individual triggers. With expanding treatment options and continued research into targeted therapies, the microbiome, and prevention, clinicians have more opportunities to help patients achieve sustained control and improve their daily lives.

Resources:

Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/

In this episode of MD Newsline, Dr. Gabriel J. Martinez-Diaz, dermatologist and psoriasis specialist, discusses the evolving landscape of psoriasis care, emphasizing the importance of treating psoriasis as a systemic inflammatory disease rather than simply a skin condition. He explores health equity challenges, the impact of comorbidities, advances in biologic therapies, and the value of a multidisciplinary approach to patient care.

Dr. Martinez-Diaz highlights the need for comprehensive screening, ongoing monitoring, and patient education to improve outcomes for individuals living with psoriasis. He also shares insights into emerging treatment options and the future of personalized psoriasis management.

Episode Highlights: Psoriasis as a Systemic Disease

Dr. Martinez-Diaz explains that psoriasis extends beyond the skin and is associated with chronic inflammation throughout the body. He discusses how psoriasis can affect cardiovascular health, metabolic health, liver function, and overall quality of life.

Health Equity and Access to Care

The conversation explores disparities in dermatologic care and the importance of ensuring equitable access to diagnosis, treatment, and long-term disease management for diverse patient populations, including individuals with skin of color.

Advances in Biologic Therapies

Dr. Martinez-Diaz reviews the evolution of biologic therapies and targeted treatments for psoriasis. He discusses how IL-17 and other immune-targeted therapies have transformed disease management, providing higher rates of skin clearance and improved patient outcomes.

Screening and Monitoring for Comorbidities

Patients with psoriasis often face increased risks for psoriatic arthritis, obesity, metabolic syndrome, cardiovascular disease, and other chronic conditions. Dr. Martinez-Diaz emphasizes the importance of proactive screening and collaboration with primary care physicians and specialists.

Patient Education and Preventive Care

The discussion highlights the role of vaccination updates, cancer screenings, and regular skin examinations for patients receiving systemic therapies. Early intervention and preventive care remain key components of successful long-term management.

A Multidisciplinary Approach to Care

Dr. Martinez-Diaz shares how dermatologists can work alongside rheumatologists, endocrinologists, primary care physicians, and other healthcare professionals to provide comprehensive care that addresses the full spectrum of a patient's health needs.

Emerging Research and Future Therapies

Looking ahead, Dr. Martinez-Diaz discusses the growing pipeline of oral therapies and next-generation treatments that may offer faster results, improved convenience, and expanded options for patients with various forms of psoriasis.

Key Takeaway

Psoriasis is far more than a skin disease. Effective management requires a comprehensive, patient-centered approach that addresses systemic inflammation, comorbid conditions, preventive care, and health equity. Through ongoing innovation and multidisciplinary collaboration, healthcare providers can help patients achieve better long-term outcomes and improved quality of life.

Resources:

Website: https://mdnewsline.com/

Newsletter: https://mdnewsline.com/subscribe/Connect with Dr. Gabriel J. Martinez-Diaz: Here

In this episode of MD Newsline, Dr. Michael A. Tomeo, a board-certified dermatologist and clinical researcher, explores the complexities of Chronic Spontaneous Urticaria (CSU), commonly known as chronic hives. He discusses the underlying role of mast cells and histamine, the diagnostic process, current treatment guidelines, and the exciting emergence of targeted biologic therapies that are transforming patient care.

Dr. Tomeo explains how chronic hives can significantly impact quality of life, affecting sleep, work productivity, and emotional well-being. He also highlights the importance of accurate diagnosis, patient self-monitoring, and the growing understanding of mast cell biology that is leading to safer and more effective treatment options.

Episode Highlights

Understanding Chronic Spontaneous Urticaria Dr. Tomeo explains that chronic spontaneous urticaria is characterized by recurring hives lasting longer than six weeks. He discusses how mast cell activation and histamine release drive symptoms and how CSU differs from allergic reactions caused by external triggers.

The Impact of Chronic Hives on Daily Life Beyond itching and visible skin lesions, chronic hives can disrupt sleep, impair work performance, and significantly reduce quality of life. Dr. Tomeo also discusses more serious manifestations such as angioedema and the potential risk of anaphylaxis.

Diagnostic Evaluation and Differential Diagnosis A thorough patient history and physical examination remain the cornerstone of diagnosis. Dr. Tomeo reviews the role of laboratory testing, including CBC, inflammatory markers, ANA testing, thyroid antibodies, and immunoglobulin levels, to help identify underlying causes and distinguish CSU from conditions such as urticarial vasculitis.

Current Treatment Guidelines Treatment typically begins with non-sedating antihistamines, which may be increased up to four times the standard dose when necessary. Dr. Tomeo discusses the use of H1 and H2 blockers and explains when clinicians should consider escalating therapy for patients who remain symptomatic.

The Growing Role of Biologic Therapies Dr. Tomeo highlights the success of biologic therapies such as omalizumab (Xolair), which targets IgE and helps reduce mast cell activation. He also discusses emerging therapies that target upstream inflammatory pathways, including BTK inhibitors and KIT receptor inhibitors.

Advances in Mast Cell Biology A deeper understanding of mast cell signaling pathways is opening new opportunities for treatment. Researchers are now targeting the cellular mechanisms responsible for histamine release rather than simply blocking histamine after it is produced.

The Gut-Skin Connection Dr. Tomeo explores how gut health and inflammation may influence immune system activity and skin disease. He discusses the concept of increased intestinal permeability and the potential role of dietary modifications in improving inflammatory conditions.

Patient Self-Advocacy and Disease Tracking Keeping a detailed symptom diary can help patients and clinicians identify patterns, monitor treatment response, and better characterize disease severity. Dr. Tomeo encourages patients to document symptoms, medications, and potential exposures to improve care.

Key Takeaway

Dr. Tomeo emphasizes that chronic spontaneous urticaria is far more than a simple skin condition. Advances in immunology and mast cell research are leading to highly targeted therapies that offer improved symptom control, enhanced safety profiles, and renewed hope for patients living with chronic hives. Early diagnosis, individualized treatment plans, and strong patient-clinician communication remain essential for achieving the best outcomes.

Resources

Website: https://mdnewsline.com/

Newsletter: https://mdnewsline.com/subscribe/

Contact with Dr. Michael A. Tomeo: Here

In this episode of MD Newsline, Dr. Collette Honore, a board-certified dermatologist, discusses the evolving landscape of psoriasis diagnosis and treatment. Drawing on years of clinical experience, she shares practical insights into identifying psoriasis across diverse skin tones, selecting appropriate biologic therapies, managing treatment resistance, and addressing complex cases involving psoriatic arthritis, metabolic syndrome, inflammatory bowel disease, and severe disease variants.

Dr. Honoré also highlights the importance of health equity in dermatology, the unique challenges of diagnosing psoriasis in skin of color, and the need for clinicians to listen closely to patients while tailoring treatment plans to individual needs and lifestyles.

Episode Highlights: Diagnosing Psoriasis Across Diverse Patient Populations

Dr. Honoré explains why psoriasis can present differently in patients with skin of color and emphasizes the importance of careful examination rather than relying solely on textbook descriptions. She discusses common diagnostic pitfalls and the value of skin biopsies when the diagnosis is uncertain.

Health Equity and Psoriasis in Skin of Color

Patients with skin of color often experience delayed diagnosis and undertreatment. Dr. Honoré shares strategies for improving recognition of psoriasis in diverse populations and ensuring equitable access to effective therapies.

Choosing the Right Biologic Therapy

Selecting a biologic requires consideration of disease severity, body surface area involvement, lifestyle factors, comorbidities, and patient preferences. Dr. Honoré reviews the role of IL-17 inhibitors, IL-23 inhibitors, TNF inhibitors, and other treatment options in modern psoriasis management.

Managing Nail, Scalp, Palmoplantar, and Genital Psoriasis

Certain psoriasis presentations can significantly affect quality of life despite limited body surface area involvement. Dr. Honoré discusses biologic therapies that have demonstrated effectiveness in difficult-to-treat areas, including the scalp, nails, palms, soles, and genital regions.

Psoriatic Arthritis and Associated Comorbidities

Psoriasis is more than a skin disease. Dr. Honoré highlights the importance of screening for psoriatic arthritis, metabolic syndrome, cardiovascular disease, and inflammatory bowel disease when developing treatment plans.

Addressing Treatment Failure and Biologic Resistance

When patients lose response to therapy, clinicians must determine whether to optimize treatment, combine therapies, or switch biologic classes. Dr. Honoré explains her approach to managing primary and secondary treatment failure while minimizing the risk of antibody formation.

Monitoring Patients on Systemic Therapy

Regular follow-up and laboratory monitoring remain critical for patients receiving methotrexate and biologic therapies. Dr. Honoré discusses practical monitoring schedules and how she balances safety with long-term treatment success.

Managing Severe and High-Risk Psoriasis Cases

From erythrodermic psoriasis to pustular disease and severe palmoplantar involvement, Dr. Honoré shares real-world experiences managing complex patients and explains when hospitalization becomes necessary.

Practical Pearls for Community Dermatologists

Dr. Honoré concludes with actionable recommendations for clinicians, including the importance of comprehensive patient histories, awareness of medication triggers, recognition of psoriasis in children, and early intervention to prevent long-term complications.

Key Takeaway

Dr. Honoré emphasizes that successful psoriasis management requires individualized care, careful attention to comorbidities, and a willingness to adapt treatment strategies over time. By improving diagnostic accuracy, embracing newer biologic therapies, and addressing disparities in care, clinicians can significantly improve outcomes and quality of life for patients living with psoriasis.

Resources:

Website: https://mdnewsline.com/

Newsletter: https://mdnewsline.com/subscribe/

Contact with Dr. Collette Honore: Here

In this episode of MD Newsline, Dr. Neelam Vashi, board-certified dermatologist at the Dermatology Institute of Boston, provides a comprehensive overview of psoriasis as a chronic immune-mediated systemic condition. She discusses how our understanding of psoriasis has evolved beyond a "skin disease" to a disorder with important systemic implications, including joint disease and cardiometabolic risk.

Dr. Vashi shares practical insights into diagnosis, screening for comorbidities, treatment selection across disease severities, and the rapidly advancing biologic landscape. She also addresses common misconceptions, adherence challenges, and the psychosocial impact of psoriasis.

Episode Highlights: Understanding Psoriasis as a Systemic Disease

Psoriasis is a chronic immune-driven condition that leads to thickened, inflamed skin—but its impact goes far beyond the surface. Dr. Vashi explains the importance of recognizing systemic inflammation, including joint involvement and cardiovascular risk.

Screening for Psoriatic Arthritis

Early identification of joint symptoms is critical. Dr. Vashi outlines simple screening questions clinicians can use in busy practices and emphasizes timely rheumatology referral to prevent permanent joint damage.

Cardiometabolic Risk and Lifestyle Counseling

Psoriasis is associated with increased cardiovascular risk due to systemic inflammation. Dr. Vashi discusses the importance of blood pressure monitoring, smoking cessation, weight management, and heart-healthy lifestyles.

Genetics and Environmental Triggers

Both genetic predisposition and environmental factors—such as infections, stress, and immune triggers—play roles in disease onset and flares. Adult-onset psoriasis is common, even in patients without childhood history.

Treatment Decision-Making: Topicals to Systemics

Treatment is individualized based on disease severity, body surface area, location, and quality-of-life impact. Dr. Vashi reviews when to use:

· Topical therapies (corticosteroids, vitamin D analogs)

· Phototherapy

· Oral small molecules (PDE4 and TYK2 inhibitors)

· Biologic therapies (TNF-alpha, IL-17, IL-23 inhibitors)

The Biologic Era: Clear to Almost Clear Skin

Modern targeted biologics have transformed moderate-to-severe psoriasis care, making clear or nearly clear skin an achievable goal for many patients.

Managing Special Populations

Treatment strategies may shift in pregnancy, pediatrics, older adults, and patients with liver, kidney, or inflammatory bowel disease. Shared decision-making remains central.

Difficult-to-Treat Areas

Scalp, nails, palms, soles, genital, and inverse psoriasis require tailored approaches and careful formulation selection to minimize irritation and maximize adherence.

Addressing Treatment Fatigue and Adherence

With psoriasis being chronic, long-term management is key. Extended dosing intervals and maintenance strategies help reduce treatment fatigue.

Common Misconceptions

Dr. Vashi dispels myths that psoriasis is contagious, caused by poor hygiene, or triggered directly by specific foods. Education remains essential for both patients and families.

Post-Inflammatory Pigment Changes

After inflammation resolves, patients may experience hyperpigmentation, hypopigmentation, or erythema—particularly in individuals with darker skin tones. Early aggressive treatment may reduce pigmentary changes.

Key Takeaway

Psoriasis is a systemic inflammatory condition that requires comprehensive, patient-centered care. With modern therapies—including highly targeted biologics—clinicians can achieve clear or nearly clear skin while also addressing joint disease, cardiometabolic risk, and quality-of-life concerns. Early intervention, shared decision-making, and ongoing monitoring are critical to optimizing long-term outcomes.

Resources:

Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/

Contact with Dr. Neelam Vashi: Here

In this episode of MD Newsline, we sit down with Dr. Meena Singh, a board-certified dermatologist and dermatologic surgeon, to discuss psoriasis—its causes, diagnosis challenges, and the latest advancements in treatment. Dr. Singh provides valuable insights into how psoriasis presents in different skin tones, the role of the gut microbiome, and emerging biologic therapies. She also highlights the importance of early diagnosis, collaborative care between primary physicians and dermatologists, and the potential impact of lifestyle modifications.

Episode Highlights:

Psoriasis Risk Factors & Diagnosis

Psoriasis is a multifactorial condition influenced by genetics, immune markers, and environmental triggers. While genetic predisposition plays a role, studies show that even identical twins do not always share the condition. Researchers have also identified gut microbiome profiles that may contribute to immune dysregulation, further linking intestinal health to psoriasis. The condition affects 2% of the general population, but for individuals of African descent, it has a higher impact on quality of life, likely due to delayed diagnosis and differences in presentation.

Diagnosing psoriasis presents unique challenges, particularly in skin of color, where the condition may not have the typical silvery scale seen in lighter skin tones. Many patients initially try natural remedies before seeking medical attention, which can lead to delays in diagnosis and treatment. The journey from primary care to dermatology is often lengthy, and even when patients do seek care, misdiagnosis remains a concern. Psoriatic arthritis, a common comorbidity, is also frequently underdiagnosed, as many patients do not initially recognize joint pain as a symptom.

Challenges in Diagnosis & Gaps in Care

Severity of psoriasis is graded using the PASI Index, which assesses body surface area affected and symptom intensity. Mild cases are often treated with topical steroids, vitamin D analogs, and newer topical JAK inhibitors, while moderate to severe cases may require biologic therapies targeting specific inflammatory pathways like IL-17, IL-12/23, and JAK inhibitors. Recent advancements have led to highly effective biologic medications, and researchers are now exploring oral small molecules that could provide targeted treatment without injections.

The Future of Psoriasis Treatment

Looking ahead, the future of psoriasis treatment is shifting toward personalized medicine, with research focusing on genetic and cytokine profiling to tailor therapies to individual patients. While there is still no cure, patients can achieve remission for months or even years with the right combination of therapies. In addition to medical treatments, lifestyle modifications such as diet and exercise can play a significant role in reducing inflammation and improving overall health. Collaboration between dermatologists and rheumatologists is crucial in managing both psoriasis and its associated conditions, such as psoriatic arthritis, cardiovascular disease, and inflammatory bowel disease.

As research continues to evolve, new treatment options are on the horizon that may revolutionize psoriasis care. However, psoriasis remains a chronic condition, and ongoing management is essential to maintaining a high quality of life.

Key Takeaway:

Psoriasis in skin of color is often misdiagnosed because it appears more purple or hyperpigmented rather than the classic red plaques with silvery scale, leading to delayed diagnosis and treatment. New biologic therapies, including IL-17 and IL-12/23 inhibitors, have significantly improved outcomes for moderate to severe cases, with promising oral treatments on the horizon. Psoriatic arthritis is a common but underdiagnosed condition, as many patients don't recognize joint pain as a symptom, making early detection by dermatologists crucial.

Resources & Links:

Website: MD Newsline Newsletter: Subscribe Here

Connect with Dr. Meena Singh: Skin and Hair Center